Shire plc and Shionogi & Co Ltd have announced that Shionogi submitted a New Drug Application (NDA) for the manufacturing and marketing in Japan of S-877503 (guanfacine hydrochloride prolonged release tablets), for the treatment of ... Bio Spectrum Asia, 1 day ago
Shionogi files NDA in Japan for ADHD treatment for children - Pharma Letter, 23 hours ago
Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD Treatment for Children - TickerTech.com, 2 days ago
3 images for "Shionogi"
ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has formalised its collaboration with Janssen Sciences Ireland UC (Janssen) to develop the first long-acting two-drug HIV injectable regimen. Under the deal, the ...Pharmaceutical Technology, 1 month ago ViiV Healthcare And Janssen Sciences Confirm Phase III Clinical Trials For HIV Cure, Involves Cabotegravir & Rilpivirine Drugs Christian Post, 3 weeks ago ViiV Healthcare collaborates with Janssen to develop long-acting, two drug injectable regimen for treatment of HIV-1 infection PharmaBiz, 1 month ago
This new contract succeeds the relationship with former partner Meiji Seika Pharma Singapore : Mundipharma and Shionogi has announced a new exclusive sales collaboration contract for its ISODINE brand in Japan. Under the contract, Shionogi will ...Bio Spectrum Asia, 1 month ago Sales and Distribution Collaboration of ISODINE(R) Brand Yahoo! Finance, 2 months ago
lly integrated speciality pharmaceutical company focused on developing, manufacturing and commercialising treatments for pain and other conditions, has terminated its collaboration with Japanese firm Shionogi Limited concerning its abuse-deterrent, ...Manufacturing Chemist, 2 months ago Egalet terminates drug collaboration with Shionogi Seeking Alpha, 2 months ago Egalet Cuts Off Drug Partnership with Shionogi 12/4/2015 ClinicSpace, 2 months ago Egalet ends partnership with Shionogi to develop hydrocodone drug candidate Pharma Letter, 2 months ago
SHIONOGI : New Opiate Receptors Data Have Been Reported by Investigators at Shionogi & Co. Ltd. (Identification of a Conformational Equilibrium That...
New Opiate Receptors Data Have Been Reported by Investigators at Shionogi & Co. Ltd. (Identification of a Conformational Equilibrium That Determines the Efficacy and Functional Selectivity of the mu-Opioid Receptor) By a News Reporter-Staff News ...4 Traders, 1 week ago Acute Market Reports: Shionogi & Co., Ltd. - Product Pipeline Review - 2015 Bloomberg, 1 month ago
Shionogi Inc. Initiates Phase 3 Clinical Study Of Osphena For The Treatment Of Postmenopausal Vaginal Dryness
By a News Reporter-Staff News Editor at Cancer Weekly Shionogi Inc. announced the company has initiated a Phase 3 clinical trial to evaluate the safety and efficacy of Osphena() (ospemifene) for the treatment of moderate to severe vaginal dryness, a ...Pharmacy Choice, 1 month ago Shionogi begins phase 3 study of Osphena to treat postmenopausal vaginal dryness PharmaBiz, 2 months ago Shionogi begins Phase III trial of Osphena to treat postmenopausal vaginal dryness Drug Development Technology, 2 months ago
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection
-- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with Janssen Sciences Ireland UC (Janssen) for the phase III investigation and commercialisation of ...Drugs.com, 1 month ago PFIZER : ViiV Healthcare : to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection 4 Traders, 1 month ago ViiV Healthcare accused of blocking access to life-saving HIV drugs Pharma Letter, 2 days ago GSK744 (Cabotegrevir)/Rilpivirine Long-Acting Injectable Maintenance Therapy Phase 3 Study Start Date Announced - ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV National AIDS Treatment Advocacy Project, 1 month ago
Casper Pharma launches commercial operations with the acquisition of four brand pharmaceutical products from Shionogi US Casper Pharma LLC 7 minutes ago Done EAST BRUNSWICK, N.J., Jan. 8, 2016 /PRNewswire-iReach/ -- Casper Pharma LLC, a New ...Yahoo! Finance, 1 month ago
More from: Ulitzer, Town Hall...and 22 other sources
GSK said the acquisitions would provide ViiV Healthcare, its HIV unit in which Pfizer and Shionogi are junior partners, with new opportunities for growth. LONDON: Pharmaceutical group GlaxoSmithKline said its majority-owned HIV business would buy drugs at ...Economic Times, 1 month ago UPDATE 1-GSK to buy HIV drugs from Bristol-Myers Squibb for initial $350 mln Reuters UK, 1 month ago
Response Biomedical Announces Strategic Alliances in Japan with Alere Medical and Long Time Partner Shionogi
Today's BC Tech News Company Snapshot ACL Services Ltd. Vancouver, BC (InfoTech) 177 Employees In BC (213 Total) Founded: 1987 About ACL ACL delivers technology solutions that are transforming audit and risk management ...BC Technology, 2 months ago Response Biomedical Corp. (RPBIF: OTCQB) | Response Biomedical Announces Strategic Alliances in Japan with Alere Medical and Long Time Partner Shionogi OTC Markets, 2 months ago Response to distribute BNP in Japan through Alere Stockwatch, 2 months ago
on your WebpageAdd Widget >Get your members hooked!